Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All aspirin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -13% Improvement Relative Risk Hospitalization 3% Progression 0% Case 8% Aspirin for COVID-19  Prieto-Campo et al.  Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective study in Spain Fewer cases with aspirin (p=0.015) c19early.org Prieto-Campo et al., Revista Española .., Jan 2024 Favors aspirin Favors control

Impact of prior use of antiplatelets on COVID-19 susceptibility, progression, and severity: a population-based study

Prieto-Campo et al., Revista Española de Cardiología (English Edition), doi:10.1016/j.rec.2023.12.004
Jan 2024  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Aspirin for COVID-19
19th treatment shown to reduce risk in March 2021
 
*, now known with p = 0.000061 from 71 studies, recognized in 2 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Population-based case-control study of 86,602 people in Spain, shower lower risk of COVID-19 cases with low-dose aspirin, but no significant difference for severity, hospitalization, or mortality.
risk of death, 13.0% higher, OR 1.13, p = 0.38, adjusted per study, case control OR.
risk of hospitalization, 3.0% lower, OR 0.97, p = 0.64, adjusted per study, case control OR.
risk of progression, no change, OR 1.00, p = 0.98, adjusted per study, case control OR.
risk of case, 8.0% lower, OR 0.92, p = 0.02, adjusted per study, case control OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Prieto-Campo et al., 6 Jan 2024, retrospective, Spain, peer-reviewed, 6 authors. Contact: maruxa.zapata@usc.es.
This PaperAspirinAll
Impact of prior use of antiplatelets on COVID-19 susceptibility, progression, and severity: a population-based study
Ángela Prieto-Campo, Maruxa Zapata-Cachafeiro, Manuel Portela-Romero, María Piñeiro-Lamas, Adolfo Figueiras, Ángel Salgado-Barreira
Revista Española de Cardiología (English Edition), doi:10.1016/j.rec.2023.12.004
Introduction and objectives: Hypercoagulability and thromboembolism are processes that arise from severe acute respiratory syndrome coronavirus 2 infection and are responsible for a high degree of coronavirus disease 2019 (COVID-19)-related morbidity and mortality. This study sought to assess the effect of antiplatelet drugs on COVID-19 severity (risk of hospitalization and mortality), susceptibility to severe acute respiratory syndrome coronavirus 2 infection, and progression to severe COVID-19. Methods: We conducted a population-based case-control study in a northwestern region of Spain in 2020. The study involved 3060 participants with a positive polymerase chain reaction test who were hospitalized, 26 757 participants with a positive polymerase chain reaction test who were not hospitalized, and 56 785 healthy controls. Results: Triflusal seemed to be associated with a significant increase in risk of hospitalization (aOR, 1.97; 95%CI, 1.27-3.04) and susceptibility to infection (OR, 1.45; 95%CI, 1.07-1.96). It also appeared to lead to a nonsignificant increase in the risk of mortality (OR, 2.23; 95%CI, 0.89-5.55) and/or progression to more severe disease stages (OR, 1.42; 95%CI, 0.8-2.51). Aspirin seemed to be associated with a statistically significant decrease in susceptibility to severe acute respiratory syndrome coronavirus 2 infection (OR, 0.92; 95%CI, 0.86-0.98). Conclusions: Triflusal use appears to increase the risk of susceptibility to COVID-19 infection and an even higher risk of hospitalization, whereas the other antiplatelets could be associated with a reduction in the risk of the various outcomes or have no effect on risk. These findings could support reconsideration of triflusal prescription in COVID-19 pandemic situations.
Medical Devices (AEMPS), and conducted in accordance with the principles of the Declaration of Helsinki and current legislation on biomedical research. The study protocol is registered in the EU Electronic Register of Post-Authorisation Studies and is available online at https://www.encepp.eu/encepp/viewResource.htm?id=44588. Automated data extraction was performed and anonymized to ensure that the participants could not be identified and therefore it was not necessary to obtain informed consent from the participants. STATEMENT ON THE USE OF ARTIFICIAL INTELLIGENCE No artificial intelligence was used in the preparation of this article. AUTHORS' CONTRIBUTIONS A. Prieto-Campo designed study and wrote the paper. M. Zapata-Cachafeiro designed the study and wrote the paper. M. Portela-Romero designed study and revised the paper. M. Piñeiro-Lamas designed study, analyzed data and revised the paper. A. Figueiras designed the study, analyzed data, and revised the paper. A. Salgado-Barreira designed the study, analyzed data and revised the paper. All authors read and approved the final version. CONFLICTS OF INTEREST None.
References
Anninos, Andrikopoulos, Pastromas, Sakellariou, Theodorakis et al., Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness, Hellenic J Cardiol
Brown, Prescott, Applied Mixed Models in Medicine
Chow, Yin, Yamane, Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: A propensity score-matched analysis, J Thromb Haemost
Colling, Kanthi, COVID-19-associated coagulopathy: An exploration of mechanisms, Vasc Med
Connors, Brooks, Sciurba, Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19, JAMA
Corrochano, Acosta-Isaac, Mojal, Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19, J Thromb Thrombolysis
Flam, Wintzell, Ludvigsson, Mårtensson, Pasternak, Direct oral anticoagulant use and risk of severe COVID-19, J Intern Med
Gogtay, Singh, Bullappa, Scott, Retrospective analysis of aspirin's role in the severity of COVID-19 pneumonia, World J Crit Care Med
Hall, Lanes, Bollaerts, Zhou, Ferreira et al., Outcome misclassification: Impact, usual practice in pharmacoepidemiology database studies and an online aid to correct biased estimates of risk ratio or cumulative incidence, Pharmacoepidemiol Drug Saf
Ho, Dusendang, Schmittdiel, Kavecansky, Tavakoli et al., Association of chronic anticoagulant and antiplatelet use on disease severity in SARS-COV-2 infected patients, J Thromb Thrombolysis
Huber, Szucs, Rapold, Reich, Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications, BMC Public Health
Iba, Levy, The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia, Trends Cardiovasc Med
Kow, Hasan, Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta-analysis, J Thromb Thrombolysis
Lal, Garces, Bansal, Prehospital Aspirin Use and Patient Outcomes in COVID-19: Results from the International Viral Infection and Respiratory Illness Universal Study (VIRUS), Arch Bronconeumol
Merzon, Green, Vinker, The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection, FEBS J
Murdoch, Plosket, Triflusal: a review of its use in cerebral infarctino and myocardial infarction, and as thromboprophylaxis in atrial fibrillation, Drugs
Pan, Ip, Zhan, Prehospital antiplatelet medication use on COVID-19 disease severity, Heart Lung
Pearce, Analysis of matched case-control studies, BMJ
Pinheiro, Bates, Mixed-Effects Models in S and S-PLUS
Rose, Laan, Van Der, Why Match? Investigating Matched Case-Control Study Designs with Causal Effect Estimation, Int J Biostat
Rothman, Greenland, Lash, Case-Control Studies
Santoro, Nuñez-Gil, Vitale, Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry, Heart
Satué-Gracia, Vila-Córcoles, De Diego-Cabanes, Susceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain, Med Clin
Shin, Kim, Cho, Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial, Yonsei Med J
Sisinni, Rossi, Battista, Pre-admission acetylsalicylic acid therapy and impact on inhospital outcome in COVID-19 patients: The ASA-CARE study, Int J Cardiol
Soldevila, Valerio-Sallent, Roure, Drug exposure may have a substantial influence on COVID-19 prognosis among residents of long-term care facilities: an exploratory analysis, Int J Infect Dis
Su, Miao, Guo, Chen, Huang et al., Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis, Front Pharmacol
Tremblay, Van Gerwen, Alsen, Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study, Blood
Wang, Ao, Nasr, Qi, Effect of antiplatelet treatments on patients with COVID-19 infection: A systematic review and meta-analysis, Am J Emerg Med
Xu, Ilyas, Weng, Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies, Acta Pharmacol Sin
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit